The Biotech Growth Trust (LON:BIOG) Stock Crosses Below 200-Day Moving Average – Should You Sell?

The Biotech Growth Trust PLC (LON:BIOG)’s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 958.04 ($12.06) and traded as low as GBX 850.45 ($10.70). The Biotech Growth Trust shares last traded at GBX 852 ($10.72), with a volume of 48,347 shares.

The Biotech Growth Trust Price Performance

The company has a 50-day simple moving average of GBX 869.02 and a 200-day simple moving average of GBX 957.50. The stock has a market cap of £243.41 million, a PE ratio of 2.86 and a beta of 0.50. The company has a debt-to-equity ratio of 11.02, a current ratio of 0.59 and a quick ratio of 0.00.

The Biotech Growth Trust (LON:BIOG) last announced its quarterly earnings results on Wednesday, November 27th. The company reported GBX 0.20 ($0.00) earnings per share for the quarter. The Biotech Growth Trust had a return on equity of 26.96% and a net margin of 95.33%.

Insider Activity at The Biotech Growth Trust

In other The Biotech Growth Trust news, insider Hamish Baillie purchased 3,000 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were purchased at an average cost of GBX 931 ($11.72) per share, with a total value of £27,930 ($35,154.19). Also, insider Nicola Shepherd purchased 1,000 shares of the firm’s stock in a transaction on Monday, January 13th. The stock was acquired at an average cost of GBX 846 ($10.65) per share, for a total transaction of £8,460 ($10,648.21). Insiders have purchased a total of 6,222 shares of company stock valued at $5,659,584 over the last quarter. Insiders own 0.71% of the company’s stock.

About The Biotech Growth Trust

The Biotech Growth Trust seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. Performance is measured against the NASDAQ Biotechnology Index (sterling adjusted).